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Aims Noradrenaline plays an important role in the modulation of atrial electrophysiology. However, the identity of the
modulated channels, their mechanisms of modulation, and their role in the action potential remain unclear. This study
aimed to investigate the noradrenergic modulation of an atrial steady-state outward current (IKss).
Methods
and results
Rat atrial myocyte whole-cell currents were recorded at 368C. Noradrenaline potently inhibited IKss (IC50 ¼ 0.90 nM,
42.1+4.3% at 1 mM, n ¼ 7) and potentiated the L-type Ca2+ current (ICaL, EC50 ¼ 136 nM, 205+40% at 1 mM,
n ¼ 6). Noradrenaline-sensitive IKss was weakly voltage-dependent, time-independent, and potentiated by the arachidonic
acid analogue, 5,8,11,14-eicosatetraynoic acid (EYTA; 10 mM), or by osmotically induced membrane stretch. Noise
analysis revealed a unitary conductance of 8.4+0.42 pS (n ¼ 8). The biophysical/pharmacological properties of IKss
indicate a TREK-like K+ channel. The effect of noradrenaline on IKss was abolished by combined b1-/b2-adrenoceptor
antagonism (1 mM propranolol or 10 mM b1-selective atenolol and 100 nM b2-selective ICI-118,551 in combination),
but not by b1- or b2-antagonist alone. The action of noradrenaline could be mimicked by b2-agonists (zinterol and
fenoterol) in thepresenceofb1-antagonist. The actionof noradrenalineon IKss, but noton ICaL,was abolishedbypertussis
toxin (PTX) treatment. The action of noradrenaline on ICaL was mediated by b1-adrenoceptors via a PTX-insensitive
pathway. Noradrenaline prolonged APD30 by 52+ 19% (n ¼ 5; P, 0.05), and this effect was abolished by combined
b1-/b2-antagonism, but not by atenolol alone.
Conclusion Noradrenaline inhibits a rat atrial TREK-like K+ channel current via a PTX-sensitive mechanism involving co-operativity
of b1-/b2-adrenoceptors that contributes to atrial APD prolongation.
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Keywords Background K+ current † Beta-adrenoceptor † K2P channel † Steady-state outward current † Osmotic stretch †
TREK-1 † Arachidonic acid
1. Introduction
Cardiac sympathetic activity plays an important role in electrophysio-
logical responses of the atria and in the genesis of atrial tachyarrhyth-
mias.1,2 Noradrenaline is the principal neurotransmitter released
from sympathetic postganglionic fibres and acts via a1-, b1-, and b2-
adrenoceptors through multiple signalling pathways to modulate
atrial ion channel and transporter function and thereby electrophysio-
logical activity.1–3 For example, the action of b-adrenoceptor stimu-
lation on Ca2+ entry via L-type Ca2+ channel current (ICaL) and
sarcoplasmic reticulum function underlies the positive inotropic
response to sympathetic activity and, under pathological conditions
in the predisposed heart, may contribute to triggered activity
through after-depolarizations and abnormal automaticity.4,5 On the
other hand, the effects of noradrenaline on K+ channel currents are
likely to contribute changes in membrane excitability and repolariza-
tion.1,2 The inwardly rectifying background K+ current (IK1) and the
steady-state outward K+ current (IKss) have been reported to be inhib-
ited by a1- and b-adrenoceptor agonists
6–14 and may be important
in the noradrenergic control of excitability, action potential (AP)
profile, and refractoriness, and may thereby contribute to the arrhyth-
mic substrate.2,15,16
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However, the channels contributing to the effects of noradrenergic
activation on atrial IK1 and IKss and the receptor/signalling pathways
remain unresolved. Moreover, since many of the previous studies on
IK1 and IKss have been conducted using receptor-selective combinations
of agonists and antagonists, the net effect of the physiological agonist,
noradrenaline, is often unclear.6–14 IK1 is largely carried by inward recti-
fier K+ (Kir2.x) channels, although the two-pore domain K
+ (K2P)
channel, TWIK-1 (K2P1.1),may also contribute.
16,17 The inward rectifier
channels, Kir3.1 and Kir3.4, form a heteromultimeric G-protein-gated
channel that underlies the current activated by acetylcholine (IKACh)
via a pertussis toxin (PTX)-sensitive mechanism in atrial myocytes.16 A
number of K+ channels have been proposed to be involved in IKss,
although the precise molecular composition of the underlying channels
remains unclear. The voltage- and time-dependent kinetics of IKss
are distinct from those of the delayed rectifier currents, IKr and IKs.
18 The
lack of detectable inactivation, together with relative insensitivity to
4-aminopyridine (4-AP), distinguishes IKss from the ultra-rapidly activating
delayed rectifier current (IKur).
15,19 The two-pore domain K+ (K2P)
channel, TREK-1 (K2P2.1), is a weakly voltage-dependent arachidonic
acid- and mechano-sensitive channel expressed in the heart that is
suggested to contribute to IKss and is modulated by isoprenaline in atrial
myocytes.17,20–24 TASK-1 (K2P3.1) is an acid-sensitive K2P channel pro-
posed to contribute to cardiac background currents and suggested to
be under G-protein-coupled receptor control.25–30 In addition, the six
transmembrane-domain voltage-gated K+ channel, SLICK (slo2.1 or
KCa4.2), is a Ca
2+-independent homologue of the BK channel (slo1.1 or
KCa1.1) that is expressed in theheartandhasbeensuggested tocontribute
to a1A-adrenoceptor-sensitive IKss in ventricular myocytes.
14,31
Much of the work characterizing the properties of IKss and its modula-
tion by adrenoceptors has been conducted in rat cardiac myo-
cytes.6,12,14,15,20–22,26–28,30 Therefore, the objectives of this study were
to investigate the channels and the receptor pathways involved in the
effect of noradrenaline on whole-cell IKss in atrial myocytes from the rat
heart and to examine the contribution of IKss to changes in the atrial AP.
2. Methods
Further details are available in Supplementary material online.
2.1 Rat left atrial myocyte isolation
All animal procedures were approved by the ethics committee of theUniver-
sity of Bristol and performed in accordance with UK legislation [Animals
(Scientific Procedures) Act, 1986]. Left atrial myocytes were isolated from
adult male Wistar rats (200–320 g) as described previously.32
2.2 Whole-cell recording
Whole-cell currents and potentials were recorded using the whole-cell
patch-clamp technique. Myocytes were superfused with Tyrode’s solution
comprising the following (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 2.5 CaCl2, 10
D-glucose, and 5 HEPES, pH 7.4 at 368C. For whole-cell, voltage-clamp
current recording, the internal solution comprised the following (in mM):
10 NaCl, 110 KCl, 0.4 MgCl2, 5 D-glucose, 10 HEPES, 5 BAPTA, 5 K-ATP,
and 0.5 Tris–GTP, pH7.3 (KOH). Inward rectifier K+ currentswere isolated
using a voltage-ramp protocol and subtraction of the background current
obtained in K+-free external solution (see Supplementary material online,
Figure S1). For K+-free recordings, the external and internal solutions
were created by equimolar replacement of KCl with CsCl. Iso-osmotic
solution consisted of (in mM) 90 NaCl, 4 KCl, 1 MgCl2, 2.5 CaCl2, 10
D-glucose, 5 HEPES, and 100 Mannitol, pH 7.4 at 368C (osmolality ¼
305 mOsm/kg H2O).Hypo-osmotic solutionwasproducedby theomission
of mannitol (osmolality ¼ 202 mOsm/kg H2O). Recordings for power
spectral analysis were made in the presence of 10 mM nifedipine. For
current-clamp AP recording, the internal solution comprised the following
(in mM): 10 NaCl, 110 KCl, 0.4 MgCl2, 5 D-glucose, 10 HEPES, 5 K-ATP,
and 0.5 Tris–GTP, pH 7.3 (KOH). APs were elicited by 2 ms depolarizing
current pulses at 1 Hz stimulation frequency.
2.3 PTX treatment of atrial myocytes
Atrial myocytes were incubated with PTX (1.5 mg/mL) at 378C for 3 h.
Treatment with PTX under these conditions was sufficient to abolish the
activation of IKACh by 1 mM ACh.
2.4 Drugs and reagents
All reagents were purchased from Sigma-Aldrich (Poole, UK), except
PTX (Merck Chemicals Ltd, Nottingham, UK). Noradrenaline, fenoterol,
atenolol, propranolol, ICI-118,551, zinc, fluoxetine, andmibefradil were dis-
solved in deionizedwater (dH2O) as 10 mMstock solutions and dissolved to
thefinal concentration in theextracellular solutionon thedayof experiment.
Prazosin was dissolved in near-absolute ethanol tomake a 1 mM stock solu-
tion and dissolved to the final concentration in the extracellular solution on
the day of experiment. Chromanol 293B, zinterol, and nifedipine were dis-
solved in dimethyl sulfoxide to make 10 mM stock solution of each drug
and stored at2208C. 4-APwas dissolved in dH2O tomake10 mMstock so-
lution and the pH adjusted to 7.4 at 368C with HCl. To avoid oxidation,
5,8,11,14-eicosatetraynoic acid (EYTA—a non-metabolizable arachidonic
acid analogue) was dissolved in chloroform under a nitrogen atmosphere,
and all chloroform evaporated before storage at 2208C. Stock solutions
were diluted to the final concentration in the extracellular solution on
the day of experiment. 1 mMof the neurotransmitter was used as an effect-
ive concentration previously reported to inhibit IK1 and IKss.
6,7 The concentra-
tions of prazosin (5 mM), atenolol (10 mM), ICI-118,551, and propranolol
(1 mM) used were chosen to achieve maximal effective blockade of,
respectively, a1-, b1-, b2-, and combined b1-/b2-adrenoceptors.
7,33 – 35
Zinterol (1 mM) and fenoterol (10 mM) were used in the presence of
10 mM atenolol to achieve selective b2-adrenoceptor activation.
34,35
Protein kinase A (PKA) was inhibited using 10 mM H-89, a concentration
that has been shown to inhibit phosphorylation of the cardiac a1c L-type
Ca2+ channel subunit.36
2.5 Data analysis
Current and voltage recordings were analysed using IgorPro (vs3.16B,
Wavemetrics, Inc., USA). The voltage-dependence of the L-type Ca2+
current (ICaL) and the noradrenaline-sensitive steady-state outward
current were fitted with modified Boltzmann equations. The variance of
the noradrenaline-sensitive, steady-state outward current was calculated
from the integral of the spectral density function, as described previously.14
2.6 Statistical analysis
Data are presented as the mean+ SEM. Sample sizes are provided in the
figure legends (numbers of cells/numbers of animals). Statistical analyses
were performed using Prism (vs5.01, GraphPad Software, Inc., USA).
Current–voltage relations were analysed by two-way repeated-measures
(RM) analysis of variance (ANOVA) with the Bonferroni post hoc test. All
other results were analysed by one-way ANOVAwith Bonferroni’s multiple
comparisons test. A P-value of ≤0.05 was considered significant.
3. Results
3.1 Whole-cell currents modulated
by noradrenaline
Two distinct current components were activated by square-shaped
depolarizing pulses (500 ms) to potentials of 220 mV and positive:
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Figure 1 Effects of noradrenaline on L-type Ca2+ (ICaL) and steady-state currents. (A) Example traces in control solution and in the presence of nor-
adrenaline (1 mM) at 0 mV (i) and at +50 mV (ii). Inset in (i) shows the voltage protocol. Lower panel in (ii) shows the noradrenaline-sensitive current
at +50 mV calculated as Icontrol2 Inoradrenaline (scale bars, the same for upper and lower panels). (B) Mean current density–voltage relations from
seven cells (five animals) for the peak inward current (i, circles) and the steady-state current (ii, squares). Control—filled symbols; 1 mM noradren-
aline—open symbols. Solid lines in (i) represent fits to a modified Boltzmann equation. Gmax, Vrev, Vhalf, and k were, respectively, 0.265 kS F
21,
+45.8 mV, 26.9 mV, and +5.8 mV in control and 0.603 kS F21, +49.7 mV, 211.9 mV, and +5.5 mV in noradrenaline. Inset in (ii) shows the voltage-
dependence of activation for the 1 mM noradrenaline-sensitive difference current; solid line represents fit to a modified Boltzmann equation. (C) Effect
of 1 mM noradrenaline on mean background current–voltage relations (n ¼ 6/2). *P, 0.05; ***P, 0.001; two-way RM ANOVA with the Bonferroni
post hoc test. Inset shows a voltage-ramp protocol. (D) Concentration-dependent action of noradrenaline on the percentage inhibition of IKss (open
squares) and percentage increase in ICaL (filled squares) at +20 mV. Data from 4 to 16 cells/1–8 animals at each concentration. Solid lines represent a
fit to a logistic equation.
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(i) an inward current that rapidly reached a peak and subsequently inac-
tivated to a steady-state outward current level by the end of the pulse,
representing the L-type Ca2+ current (ICaL) (Figure 1Ai) and (ii) a
steady-state outward current that showed little inactivation at the end
of the pulse (Figure 1Aii). ICaL showed voltage-dependent activation
with Vhalf≈ 27 mV (k ≈ 6 mV) and a maximal inward current density
at 0 mV under control conditions (Figure 1Bi). Superfusion of the cells
with 1 mM noradrenaline produced a marked increase in ICaL across
the voltage range, and this was associated with a 2.3-fold increase in
Gmax and a5 mV negative shift in Vhalf. In addition, 1 mMnoradrenaline
also inhibited the steady-state outward current at positive potentials,
the current at +50 mV being reduced by 42.1+4.3% (n ¼ 7/5)
(Figure 1Bii). Note the time-independent nature of the noradrenaline-
sensitive outward current at +50 mV (lower panel, Figure 1Aii). The
noradrenaline-sensitive outward current component was weakly
voltage-dependent (Vhalf ¼ 2.71+3.22 mV, k ¼ 17.11+ 3.04 mV),
being activated from potentials positive to 240 mV (inset, Figure 1Bii).
The inwardly rectifying current obtained at negative potentials using a
modified ramp protocol was abolished in the absence of external K+
(see Supplementary material online, Figure S1), demonstrating the in-
volvement of Kir2.x channels.
37 While 1 mM noradrenaline inhibited
the steady-state outward currents evident at potentials positive to
240 mV (Figure 1Bii), the currents negative to240 mVwereunaffected
(Figure 1C). Thus, under the conditions of this study, noradrenaline
inhibited a time-independent, outwardly rectifying weakly voltage-
dependent current, whereas IK1 was unaffected (see Supplementary
material online, Figure S1E). Noradrenaline (1 mM) had similar effects
on whole-cell currents in isolated mouse atrial myocytes (see Supple-
mentary material online, Figure S2). The effects of noradrenaline on
the steady-state outward current were abolished in the absence of
internal and external K+, demonstrating the K+-selective nature of
the noradrenaline-sensitive IKss (see Supplementary material online,
Figure S3B). In rat atrial cells, IKss was inhibited concentration-
dependently by noradrenaline with log(IC50) ¼ 29.048+ 0.0979 M
(EC50 ¼ 0.895 nM), whereas ICaL was potentiated with a
log(EC50) ¼ 26.687+2.882 M (EC50 ¼ 136 nM) (Figure 1D). Thus,
noradrenaline was 150-fold more potent in the inhibition of IKss
than in the increase of ICaL.
3.2 Power spectral analysis of
noradrenaline-sensitive IKss
It was notable in the recordings of steady-state outward currents in the
presence of K+ that the level of noise in IKss was reduced by noradren-
aline (Figure 1Aii). This is demonstrated in Figure 2A, in which 5
DC-component-subtracted currents at+50 mV in the presenceof nor-
adrenaline (black traces) are superimposed on 5DC-subtracted control
currents (grey). This reduction in noise reflects the action of noradren-
aline on the gating of the underlying K+-selective channels. Because the
open-channel conductance is a function of the current variance, the
power spectra provide a measure of the unitary conductance.38 The
power spectra could be described by a double Lorentzian (Figure 2B),
in which the corner frequencies (mean values at +50 mV in paren-
theses), fc1 (4.1+ 1.6 Hz) and fc2 (148.5+25.3 Hz), are functions of
channel gating and the low-frequency asymptotes; S(0)1 (572+
251 pA2 s21) and S(0)2 (4.70+1.04 pA
2 s21) are functions of the
powerof the noise arising fromchannel gating (n ¼ 8/6 cells). The open-
channel conductance calculated by a linear regression of the unitary
current–voltage relations was 8.44+ 0.42 pS (Figure 2C, n ¼ 8/6).
3.3 Sensitivity of IKss to K
1 channel
modulators
The outward currents at positive potentials were reduced by the
blocker of voltage-gated K+ channels, 4-AP (3 mM),39 although nor-
adrenaline in the continued presence of 4-AP inhibited the current
further so that the response to noradrenaline at +20 mV was
reduced to 36% of control (Figure 3A and B). On the other hand,
neither the KCNQ1/IKs delayed rectifier channel blocker, chromanol
293B (10 mM),40 nor the TASK-1/TASK-3 blocker, Zn2+ (1 mM),41,42
had any significant effect on the response to noradrenaline, although
the control steady-state outward current was reduced by 28.9+4.1%
(n ¼ 5/2) in the presence of the divalent cation (Figure 3B). These data
are consistent with the proposition that TASK-1/3 contributes to an
outward current in rat atrial myocytes that is not modulated by nor-
adrenaline.On the other hand, the background currents at both positive
andnegativepotentialsweremarkedly inhibitedby theTREK-1blockers,
fluoxetine and mibefradil (see Supplementary material online,
Figure 2 Power spectral analysis of the noradrenaline-sensitive IKss. (A) Five consecutive DC-subtracted traces recorded at +50 mV in control (grey
traces) and in noradrenaline-containing (black traces) solution. (B) A representative power spectrum for the noradrenaline-sensitive current; data corres-
pond to that shown in (A). Solid line represents a fit to a double Lorentzian equation; S(0)1 ¼ 8.15 pA2 s21, fc1 ¼ 6.3 Hz, S(0)2 ¼ 1.15 pA2 s21,
fc2 ¼ 135.6 Hz. (C) Mean unitary current–voltage relations for the noradrenaline-sensitive current (n ¼ 8/6). Solid line was fitted by linear regression
assuming zero current at EK (290.9 mV).
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Figure S4).43–46 The fluoxetine- and mibefradil-sensitive difference cur-
rents reversed close to theK+ equilibriumpotential (EK), demonstrating
their K+-selectivity (see Supplementary material online, Figure S4B and
D). Most strikingly, the effect of noradrenaline on the steady-state
outward current was abolished in the presence of the TREK-1 channel
blockers (Figure 3B). TREK-1 channel currents are reported to be acti-
vated by arachidonic acid and by stretch.20–22,24,47 The effect of the non-
metabolizable analogue of arachidonic acid, EYTA (10 mM), on the
noradrenaline-sensitive current was investigated (Figure 3C). Super-
fusion of the cells with EYTA increased the steady-state outward
current at +20 mV by 38.6+16.2% (P, 0.05; n ¼ 5/3; Figure 3C).
Addition of noradrenaline in the continued presence of EYTA resulted
in a reduction of the steady-state outward current by 60.9+3.9%
(P, 0.001; n ¼ 5/3; Figure 3C), representing an augmentation of the
response to noradrenaline of 50% (Figure 3B). Similarly, hyposmotic
stretch also increased IKss at +20 mV (69.7+17.0%, n ¼ 7/2, P, 0.05),
and noradrenaline inhibited the hyposmotically potentiated current
(67.0+12.6%; P, 0.001), representing 63% augmentation of the
response to noradrenaline (Figure 3B and D).
3.4 Adrenoceptor subtypes in the
noradrenaline response
The inhibitory effect of noradrenaline on IKss at concentrations of
1–100 nM was strongly reduced by either the b1-adrenoceptor
blocker, atenolol (10 mM), or b2-selective ICI-118,551 (100 nM;
Figure 4A). However, neither antagonist was effective against the re-
sponse to 1 mM noradrenaline when applied alone (Figure 4A). On the
Figure3 Effect of K+ channelmodulators on the noradrenaline-sensitive current. (A)Mean backgroundcurrent density–voltage relations fromsix cells/
two animals in control solution (filled circles), in the presence of 4-AP (3 mM, filled squares) and in the presence of 4-AP + noradrenaline (1 mM, open
squares). Inset reproduces the effect of noradrenaline under control conditions shown in Figure 1D over the voltage range, 250 to +20 mV. 4-AP vs.
control: *P, 0.05; **P, 0.01; ***P, 0.001; inset noradrenaline vs. control: ##P, 0.01; ###P, 0.001; two-way RM ANOVA with the Bonferroni
post hoc test. (B) Effect of K+ channel modulators on the mean percentage inhibition by noradrenaline of IKss at +20 mV. Control (n ¼ 8/6), 4-AP
(n ¼ 6/2), chromanol 293 B (Chrom 293B; n ¼ 5/1), Zn2+ (n ¼ 5/2), Ba2+ (n ¼ 7/1), fluoxetine (fluox; n ¼ 7/2), mibefradil (mibef; n ¼ 6/2), EYTA
(n ¼ 5/3), and hypotonic solution (n ¼ 7/2). **P, 0.01; ***P, 0.001; one-way ANOVA with the Bonferroni multiple comparisons test vs. control.
(C) Mean background current density–voltage relations in control solution (filled circles) and in the presence of EYTA (1 mM, filled squares) and in the
presence of EYTA + noradrenaline (1 mM, open squares, n ¼ 5/3). *P, 0.05; ***P, 0.001; two-way RM ANOVA with the Bonferroni post hoc test,
EYTA vs. control. ##P, 0.01; ###P, 0.001; two-way RM ANOVA with the Bonferroni post hoc test, noradrenaline + EYTA vs. EYTA. (D) Mean back-
ground current density–voltage relations in control solution (filled circles), in the presence of hypotonic solution (filled squares) and in the presence
of hypotonic solution + noradrenaline (1 mM, open squares, n ¼ 7/2). **P, 0.01; ***P, 0.001; two-way RM ANOVA with the Bonferroni post hoc
test, hypotonic vs. control. ##P, 0.01; ###P, 0.001; two-way RM ANOVAwith the Bonferroni post hoc test, noradrenaline + hypotonic vs. hypotonic.
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other hand, the effect of 1 mM noradrenaline was markedly inhibited
when the b1- and b2-antagonists, atenolol (10 mM) and ICI-118,551
(100 nM), were applied in combination (Figure 4A). The apparent
rightward-shift in the concentration- dependence of IKss inhibition by
noradrenaline produced by either atenolol or ICI-118,551 when
applied alone, taken together with the cumulative effect against 1 mM
noradrenaline when the antagonists were applied in combination,
demonstrates the involvement of both b1- and b2-adrenoceptor sub-
types in response to noradrenaline. Consistent with this, the effect of
1 mM noradrenaline on IKss was abolished by the non-selective b1-/b2-
adrenoceptor antagonist, propranolol (1 mM; Figure 4A and B). The
effect of 1 mM noradrenaline on the steady-state outward current at
+20 mV (46.8+ 2.56%, n ¼ 13)was unaffected by thea-adrenoceptor
antagonist, prazosin (5 mM), either applied alone (46.6+4.06%, n ¼ 5)
or in combination with 10 mM atenolol (42.3+ 5.11%, n ¼ 5). IKss was
inhibited by b2-adrenoceptor-selective agonism with either zinterol
(1 mM) or fenoterol (10 mM) in the presence of 10 mM atenolol, in
a manner similar to noradrenaline, consistent with a role for
b2-adrenoceptors in the inhibition of IKss (Figure 4D and E). The augmen-
tation of ICaL by 1 mMnoradrenalinewas also completely inhibited in the
presence of propranolol (Figure 4C). The increase of ICaL by 1 mM nor-
adrenaline (201+ 54.6% at +10 mV, n ¼ 6, Figure 1Bi) was also com-
pletely abolished in the presence of the b1-adrenoceptor antagonist,
10 mM atenolol (23.1+ 2.69%, n ¼ 5). On the other hand, zinterol
hadnoeffecton ICaL (Figure4F), indicating that theeffectof noradrenaline
on ICaL was mediated predominantly by b1-adrenoceptors.
3.5 Cell signalling pathways
The b2-adrenoceptor couples with both Gs- and Gi-mediated signalling
pathways.3 Gs-protein activates the adenylyl cyclase/PKA cascade in-
volving cyclic AMP.3 The inhibitory effect of noradrenaline on the
steady-state outward current could still be observed following
Figure4 Effect of adrenoceptor antagonists on the effects of noradrenaline. (A) Effect of adrenoceptor antagonists on the concentration-dependenceof
mean percentage IKss inhibition by noradrenaline at+20 mV.Control (open circles, n ¼ 8/6), atenolol (grey-filled diamonds, n ¼ 11/4), ICI-118,551 (grey-
filledcircles,n ¼ 10/4), atenololplus ICI-118,551 (black-filled circles,n ¼ 5/2), andpropranolol (black-filleddiamonds,n ¼ 8/4). Solid line representsafit to
a logistic equation.Control data as shown in Figure1D. #P, 0.05 and###P, 0.001; two-wayANOVAwith theBonferronipost hoc test, atenolol vs. control.
$$$P, 0.001, two-way ANOVAwith the Bonferroni post hoc test, ICI-118,551 vs. control. **P, 0.01 and ***P, 0.001; two-way ANOVAwith the Bon-
ferroni post hoc test, atenolol/ICI-118,551 vs. control. &&&&P, 0.0001, Student’s paired t-test, propranolol vs. control. (B) Mean background current–
voltage relations in control (grey-filled circles), in the presence of 1 mM propranolol (black-filled circles) and in the presence of propranolol +
noradrenaline (opencircles,n ¼ 8/4).Note that the IVcurvesarealmostcompletely superimposed. (C)Mean ICaL density–voltage relations in thepresence
of propranolol (filled circles) and in the presence of propranolol + noradrenaline (open circles, n ¼ 9/4). ICaL–V relation in the presence of propranolol
alone was not significantly different from control (Figure 1Bi, P ¼ 0.1388, two-way ANOVAwith RM for voltage). (D) Mean percentage inhibition of IKss at
+20 mV by b2-agonists, noradrenaline (1 mM, n ¼ 11/4), fenoterol (10 mM, n ¼ 8/3), and zinterol (1 mM, n ¼ 6/2) in the presence of 10 mM atenolol.
(E) Effect of 1 mM zinterol on mean background current density–voltage relations in the presence of 10 mM atenolol (n ¼ 6/2). Filled circles—control;
open circles—1 mM zinterol. *P, 0.05; **P, 0.01; ***P, 0.001; two-way ANOVA with the Bonferroni post hoc test, zinterol vs. control at each
voltage. (F) Effect of 1 mM zinterol on ICaL density–voltage relations in the presence of 10 mM atenolol (n ¼ 5/2). Solid lines in (C and F) represent fits
to modified Boltzmann equations.
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treatment of the cellswith thePKA inhibitor,H-89 (10 mM), at a concen-
tration sufficient to ablate completely the augmentationof ICaL (see Sup-
plementary material online, Figure S5), indicating that PKA was not
essential to the action of noradrenaline on IKss. The role of Gi-proteins
in the inhibitory effect of noradrenaline on the steady-state outward
current was investigated by pretreatment of the cells in PTX (Figure 5).
While the effect of noradrenalineon ICaL remained intact in PTX-treated
cells (Figure 5A), the steady-state outward current inhibition was com-
pletely abolished (Figure 5B and C). Taken together, these results show
that the inhibitory effect of noradrenaline on the steady-state outward
current was mediated via a PTX-sensitive mechanism that did not
require PKA. On the other hand, b2-adrenoceptors did not contribute
to the potentiation of ICaL by noradrenaline, which likely involved
b1-adrenoceptors acting via PKA.
3.6 AP prolongation by noradrenaline
The effects of noradrenaline (1 mM) on the AP were investigated
(Figure 6). Noradrenaline caused a delay in the early and mid-phases of
repolarization, consistent with changes in ICaL and IKss (Figure 6A). The
effect of noradrenaline in the presence of the b1-antagonist, atenolol,
and the non-selective b1-/b2-blocker, propranolol, is shown in
Figure 6B and C, respectively. The effects of noradrenaline on mean AP
duration at 30% repolarization (APD30) in the absence of and the pres-
ence of the b-blockers are shown in Figure 6D. Noradrenaline caused
65% prolongation of APD30. Although b1-antagonism produced a
partial reduction in APD30 prolongation, the effect of noradrenaline
was completely abolished with combined b1-/b2-blockade using
either 100 nM ICI-118,551 in combination with 10 mM atenolol or
1 mM propranolol (Figure 6D).
4. Discussion
This study demonstrates for the first time the potent inhibition of a
steady-state outward K+ current in atrial myocytes by nanomolar con-
centrations of noradrenaline (IC50 ¼ 0.90 nM). In contrast, noradren-
aline was 150-fold less potent in potentiating ICaL (EC50 ¼ 136 nM).
Both b1- and b2-adrenoceptors were co-operatively involved in the
inhibition of IKss, which was via a PTX-sensitive pathway that did not
require PKA. On the other hand, the potentiation of ICaL by noradren-
aline was mediated via b1-adrenoceptors through PKA. The
noradrenaline-sensitive current had pharmacological and biophysical
properties consistent with the involvement of a TREK-like channel. In-
hibition of IKss contributed to the noradrenaline-induced prolongation
of the AP in atrial myocytes.
4.1 Properties of noradrenaline-sensitive
IKss
The effectively instantaneous activation of the noradrenaline-sensitive
steady-state outward current on depolarization positive to 240 mV
and the lack of time-dependent inactivation over the course of the
pulse are representative of adrenoceptor-modulated IKss in rat ven-
tricular myocytes reported previously and rule out contribution of
the transient outward current, Ito.
6,12,14 Moreover, the observation
that 36% of the noradrenaline-sensitive current remained in the pres-
ence of 3 mM 4-AP indicates that IKss was distinct from the compara-
tively 4-AP-sensitive IKur/Kv1.5 channel currents that would be
almost completely inhibited by the concentration of this voltage-gated
K+ channel blocker.15,19
Although control IKss was inhibited by Zn
2+, consistent with the con-
tributionofTASK-1 channels to thewhole-cell currents, the response to
noradrenaline was unaffected, demonstrating that this K2P channel did
not contribute to the noradrenaline-sensitive current. On the other
hand, theweak voltage-dependence, thepotentiationby the arachidonic
acid analogue, EYTA, and by osmotic stretch and the inhibition by fluox-
etine,mibefradil, andBa2+ are all properties thatnoradrenaline-sensitive
IKss shares with TREK-1 channels.
20–22,43–47 The effects of noradren-
aline on the power spectrum demonstrate unequivocally the involve-
ment of an ion channel with flickery kinetics in IKss. The calculated
unitary conductance (8.4 pS) is close to the 14 pS originally proposed
for TREK-1.48 However, unitary current recordings of TREK-1-like
Figure 5 Effect of PTX on the action of noradrenaline. (A) An
example of ICaL traces in control and 1 mM noradrenaline at 0 mV
after pretreatment with PTX. The effect of noradrenaline is compar-
able with that seen in PTX-untreated cells (Figure 1Ai). (B) An
example of ramp current traces in control and noradrenaline following
pretreatment with PTX. (C) Mean current density–voltage relations in
control (filled circles) and noradrenaline (open circles) in PTX pre-
treated cells (n ¼ 5/2). In contrast to PTX-untreated cells (Figure 1C),
the effect of noradrenaline on currents at positive potentials is lost.
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channel currents in rat cardiomyocytes have suggested a conductanceof
41 pS.21,22 The basis for the differences in reported conductance are
unclear, but a number of conductance modes for the TREK-1 channel
have been reported, and it has been suggested that the conductance
mode depends on interaction with cytosolic regulatory proteins.49 It is
conceivable, therefore, that the noradrenaline-sensitive channel repre-
sents a lower conductancemodeof TREK-1 thanwas evident previously
in cell-attached and excised-patch recordings.21,22 It is notable that IKss
was also reduced by the removal of external K+ in amanner reminiscent
of Kir channels. Nevertheless, IKss was distinct from IK1, because nor-
adrenaline had no effect on the inward rectifier currents. Interestingly,
a tendency to pore collapse and non-conductive states of the channel
in external K+-free conditions similar to Kir2.1 has recently been sug-
gested for TREK-1.50 Thus, our data are consistentwith the involvement
of a TREK-1-like channel in the noradrenaline-sensitive IKss of rat atrial
myocytes.
4.2 Inhibition of IKss is mediated via a
PTX-sensitive mechanism involving both
b1- and b2-adrenoceptors
The effect of receptor subtype-selective concentrations of aten-
olol (10 mM) and ICI-118,551 (100 nM)33–35 on the concentration
response of IKss inhibition by noradrenaline demonstrated the involve-
mentof bothb1- andb2-adrenoceptors. Either atenolol or ICI-118,551
was effective at inhibiting responses to 1–100 nM noradrenaline,
indicating co-operativity between b1- and b2-adrenoceptor pathways.
It is notable that noradrenaline was effective at inhibiting IKss at concen-
trations far below the reported dissociation constant at either b1-
(Kd 1–4 mM) or b2-adrenoceptors (Kd 4–26 mM).51–53 Interesting-
ly, it has been reported that b1-/b2-adrenoceptor subunits can form
heterodimeric receptors in cardiomyocytes that have an increased
agonist sensitivity relative to the respective homodimeric receptors.54
Moreover, the action of noradrenaline in inhibiting IKss with greater
potency than potentiation of ICaL is consistent with a previous report
of the effects of the b-agonist, isoprenaline, on IKss and ICaL in rat ven-
tricular myocytes.12
The abolition of IKss responses following pretreatment with PTX
demonstrated the involvement of a Gi-protein, consistent with
reports of coupling of b1-, as well as b2- adrenoceptors, to Gi-protein
pathways in cardiomyocytes.55,56 The involvement of b-adrenoceptors
in the inhibition of TREK-1 channel-like currents in rat atrial myocytes
has been suggested previously.21 However, the inhibitory response to
noradrenaline was not abolished by treatment with H-89, indicating
that PKA was not required for the regulation of IKss. Although the
effect of noradrenaline on IKss was reduced in the presence of H-89,
this was likely due to non-specific actions of the PKA inhibitor.57 The
requirementof bothb1- andb2-adrenoceptors for IKss inhibition by nor-
adrenaline and the PTX sensitivity of this response suggest that the
receptors and Gi-proteins modulating TREK-like channel activity are
co-localized, consistent with the ability of b1-/b2-adrenoceptor sub-
types to form heterodimers.54
Figure6 Effects of noradrenaline onAPs. (A) RepresentativeAPs in control and in 1 mMnoradrenaline. (B) RepresentativeAPs in the presence of 10 mM
atenolol and 1 mMnoradrenaline in the continued presence of atenolol. (C) Representative APs in the presence of 1 mMpropranolol and 1 mMnoradren-
aline in the continued presence of propranolol. (D) Mean noradrenaline-induced percentageAPD30-change (%DAPD30) in the absence of antagonist (NA,
n ¼ 5/4), in the presence of 10 mM atenolol (+AT, n ¼ 8/4), in the presence of 100 nM ICI-118,551 plus 10 mM atenolol (+AT/ICI, n ¼ 6/2), and in the
presence of 1 mM propranolol (+PRO, n ¼ 5/2). **P, 0.01; ***P, 0.001; one-way ANOVAwith the Bonferroni post hoc test.
R.C. Bond et al.Page 8 of 10
 at U
niversity Library on Septem
ber 9, 2014
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
The potentiation of ICaL by noradrenaline was mediated predomin-
antly via a PTX-insensitive, H-89-sensitive b1-adrenoceptor pathway,
consistent with an essential role for PKA in the regulation of cardiac
L-type Ca2+ channels.56,58 ICaL was not potentiated by zinterol, indicat-
ing that, in contrast to ventricular cells, b2-adrenoceptors were not
involved in the regulation of L-type Ca2+ channels in rat atrial myo-
cytes.56,59 Consistent with this view, the potentiation of ICaL by 1 mM
noradrenalinewascompletely abolished in thepresenceofb1-receptor-
selective atenolol.
4.3 Noradrenergic inhibition of IKss
contributes to AP prolongation
Noradrenaline caused prolongation of the AP at relatively depolarized
potentials, but had little effect closer to the restingmembrane potential.
The prolongation of APD30 by noradrenaline was consistent with
the actions of noradrenaline on ICaL and IKss. Under the conditions of
this study, it was possible to discriminate between the actions of nor-
adrenaline on ICaL and IKss through differences in their sensitivity to
b-adrenoceptor-selective antagonists. For example, in the presence of
atenolol alone, noradrenergic potentiation of ICaL would be blocked
while the inhibition of IKss would remain intact. On the other hand, in
the presence of combined b1-/b2-antagonism, the effect of noradren-
aline on IKss would also be reduced. Thus, the correlation between
the degree of noradrenaline-induced APD30 prolongation and the
degree of noradrenergic inhibition of IKss in the presence of b1-/b2-
non-selective propranolol, b1-selective atenolol, and b2-selective
ICI-118,551 in combination and atenolol alone (see Supplementary ma-
terial online, Figure S6) illustrated the contribution of IKss to the noradre-
nergic prolongation of the AP. AP prolongation through IKss inhibition is
likely to affect sarcolemmalCa2+fluxes via L-typeCa2+ channels and the
Na+/Ca2+ exchanger and thereby to contribute to the effects of
noradrenaline on atrial contractility and arrhythmogenesis.
4.4 Possible physiological significance
of noradrenaline-sensitive IKss
It has not been possible, to date, to measure directly the concentration
of noradrenaline achieved at the neuroeffector junction of cardiac post-
ganglionic fibres during sympathetic activity, but it is generally estimated
to be .100 nM.60 The EC50 for noradrenergic potentiation of ICaL
corresponds well with this value, consistent with the potentiation via
b1-adrenoceptors of atrial Ca
2+ entry during sympathetic activity.2,4
The ‘basal’ concentration of noradrenaline at the cardiac neuroeffector
junction is also unknown, but it is likely to be similar to circulating
concentrations of noradrenaline, which are reportedly very low
(1–2 nM).60 Since the IC50 for inhibition of IKss by noradrenaline was
0.90 nM, it seems likely that this current would be inhibited, contrib-
uting toAPprolongation at relativelymodest levels of sympathetic activ-
ity. On the other hand, this TREK-like channel current is activated by
stretch and may make a greater contribution to AP repolarization
under physiological mechanical loads in vivo.22 The inhibition by
noradrenaline may provide a mechanism by which AP configuration is
optimized to mechanical load and degree of autonomic activation.
4.5 Limitations
This study provides good evidence of a role for a TREK-like IKss in repo-
larization of rat atrial myocytes and demonstrates the existence of a
similar noradrenaline-sensitive current in mouse atrial cells. Expression
of TREK-1 has recently been demonstrated in the human heart.61
However, it is currently unclear to what extent IKss contributes to the
repolarization of the human atrium. Moreover, it is not clear whether
these TREK-like currents are atrial selective. Further work is therefore
merited to establish the contribution of IKss and K2P channels to
human cardiac electrophysiology.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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